Sunday February 14, 2010
Female preponderance in ibutilide-induced torsade de pointes

Objective: Ibutilide, a class III antiarrhythmic agent used for pharmacological cardioversion of atrial arrhythmias, has a potential to cause QT-interval prolongation and torsade de pointes. Purpose of this study was to determine whether women are more prone to develop ibutilide-induced torsade de pointes.

Methods: All clinical trials, cases, case series, and related articles in English-language in addition to 51 patients from our institution on the subject were examined.

Results: In a database derived from 23 reports in literature and from our institution, 1720 patients received ibutilide for cardioversion of atrial arrhythmias. Only in 87% (n=1492) patients, data were reported whether or not ibutilide caused torsade de pointes.

The overall incidence of torsade de pointes was 3.9% (n=58) patients.

Data on sex distribution of ibutilide-induced torsade de pointes was available in 73% (n=1096) patients. Torsade de pointes developed in 17 (5.6%) of 304 women and 24 (3%) of 792 men (P=0.05). It occurred during or within 45 min after completion of the infusion of ibutilide.

Treatment instituted was with intravenous magnesium sulfate alone in 14% (n=8) patients, magnesium sulfate plus lidocaine in 5% (n=3) patients, magnesium sulfate with electrical cardioversion in 17% (n=10) patients, electrical cardioversion alone in 19% (n=11) patients, and precordial thump in 3% (n=2) patients.

In 41% (n=24) of patients who developed torsade de pointes, it resolved without treatment.

There were no reported deaths secondary to torsade de pointes associated with ibutilide infusion.

Conclusion: Incidence of ibutilide-induced torsade de pointes is higher in women than in men. Greater caution must be observed while using ibutilide in women.



Female preponderance in ibutilide-induced torsade de pointes - International Journal of Cardiology, Volume 95, Issue 2, Pages 219-222